Abstract 100P
Background
Rapid diagnostic services (RDS) are a two-week wait pathway for patients with non-specific symptoms (e.g., weight loss and fatigue), concerning of malignancy, that do not fulfil criteria for a site-specific cancer referral. Notoriously, patients without clear red flag symptoms have longer time to diagnosis and worse outcomes. RDS are being expanded across England to provide a new referral route for this cohort of patients to improve time to diagnosis and the patient journey. This study aimed to create a cancer risk stratification tool based on levels of standard serum biomarkers to help clinicians triage patients attending Guy’s RDC.
Methods
We analysed a panel of standard serum biomarkers assessed at referral for patients seen at Guy´s RDC between December 2016 and April 2022. Latent class analysis (LCA) was applied to investigate classes of individuals characterized based on their biomarker values (according to medical cut-offs), which were then examined as predictors of cancer using multivariate logistic regression. The abnormal biomarkers identified within LCA class with higher risk of cancer were used to create a scoring system, which was then developed into a cancer stratification tool.
Results
LCA identified four biomarker profiles: 1) normal values for all markers (51% of population); 2) abnormal values for haemoglobin, creatinine, and inflammatory markers (28%); 3) abnormal values for neutrophil to lymphocyte ratio, neutrophils, and inflammatory markers (12%); 4) abnormal values for multiple (n=10) markers (8%). Compared with class 1, class 4 had an increased risk of cancer (Odds ratio (OR) 6.33; 95% Confidence Interval (CI) 5.92-6.77). Based on the biomarkers identified in class 4 we created a score giving one point to each abnormal biomarker. A score of >=2 was associated with an increased risk of cancer (OR 3.09; 95%CI 2.91-3.27), as compared to a score of <2 (Area under the curve for test-training split: 0.68, C-index: 0.7).
Conclusions
Our innovative approach to triage patients with non-specific symptoms in the RDC for cancer diagnosis suggests that a combination of 10 standard biomarkers could be used to help facilitate a more efficient diagnosis of cancer when presenting with vague symptoms.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract